Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-DAPPER
PACTR202111570999061Phase 4Not yet recruiting
- Sponsor
- National Institute of Mental Health
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fluoxetine in major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) (3 arms), sponsored by National Institute of Mental Health. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on PACTR202111570999061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202111570999061.